Fisher Wallace Laboratories offering is now closed and is no longer accepting investments.


Prescription Wearables For Mental Health

Fisher Wallace manufactures and markets prescription-only brain stimulation wearables that have been cleared by the FDA to treat depression, anxiety, and insomnia. The technology comfortably stimulates the brain to produce serotonin, lower cortisol, and modulate brain activity. The company is VC-backed and led by CEO Kelly Roman, who has helped pioneer the category since 2009.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.
Fisher Wallace Laboratories

$1,161,578.55 Raised

Reasons to Invest

  • Over $30 million in lifetime net revenue and 80,000 sales of Version 1 device; Version 2 designed by Eric Fields (Beats, Nest) and engineered by Alloy Product Development (Beats, Microsoft) for release in 2023.

  • Currently FDA-Cleared and pursuing new FDA-Approval for the treatment of Major Depressive Disorder.

  • $5.7 million raised previously on StartEngine, and $2.5 million raised from VC firm SHUFL Capital.


Meet Fisher Wallace: developing a new standard of care

*These products are currently under development and not yet available on the market.

Fisher Wallace has developed a wearable medical device that electrically stimulates the brain to treat psychiatric disorders without causing serious side effects. The company’s proof-of-concept device, the Fisher Wallace Stimulator®, has been cleared by the FDA to treat depression, anxiety and insomnia and has been purchased by over 80,000 patients.

In 2021, the company submitted data to the FDA from anxiety and insomnia research conducted during the pandemic and is awaiting the agency's decision on new anxiety and insomnia clearances. In early 2022, the company launched a pivotal clinical trial to obtain FDA-Approval for the treatment of Major Depressive Disorder. The depression data submission deadline is December 11, 2022, and the FDA is expected to render an Approval decision by early 2023. 

In a pilot study conducted at Mount Sinai Beth Israel Hospital in 2015, subjects who used an active Fisher Wallace device experienced durable depression relief, while subjects who used a placebo device returned to baseline. This scientific data, in combination with the anecdotal data from Fisher Wallace's 80,000+ patients and 14,000+ prescribers, informed the company's decision to raise capital to pursue full FDA-Approval.

In tandem with scientific research, the company is developing a Version 2.0 device (see images above) under a new brand name that will feature precisely the same therapeutic output as Version 1.0 but with industrial design from Eric Fields - the award-winning designer of the Nest thermostat and the Beats pill. Alloy Product Development - the engineers of Beats and Microsoft products - is providing the electrical and mechanical engineering. 

In 2023, Fisher Wallace intends to disrupt the mental health industry with a beautifully designed, FDA-Approved Version 2.0 device that is affordable out-of-pocket and prescribed via telemedicine on its e-commerce store.

The market

The US spends over $225 billion a year on mental health treatment

Source: NAMI

Depression and anxiety affect one in three Americans (source and source), and at least 50 million Americans suffer from a sleep disorder (source). 

the problem

Side effects, modest efficacy, and high cost make drug therapy and behavioral therapy insufficient solutions

SSRI medication causes side effects that include nausea, sexual problems and weight gain (source). The average cost of seeing a therapist is $100 - $200 per session (source) and as many as half of all patients fail to complete the “homework” associated with cognitive behavioral therapy that’s needed to experience results (source).

the solution

Rapid treatment with minimal side effects

Patients use the technology for 20 minutes, once or twice a day, easily integrating usage into their daily routine. The company provides its customers a 30-day full refund policy, allowing them to try the device without the risk of losing any money if treatment is unsuccessful. In a recent customer survey, 76.5% of Fisher Wallace customers stated that they intend to use the device for the rest of their life to maintain mental health and cognitive performance, and 26.9% stated that the device is more important than their cell phone.

*These products are currently under development and not yet available on the market.

our traction

Proven product-market fit and scalability

By leveraging a vertically integrated e-commerce model in which a free prescription process is integrated into checkout, Fisher Wallace has succeeded in generating over $30 million in net revenue.

The Seattle Police Department launched a pilot study with the Fisher Wallace device in January 2022 and it is scheduled to be completed by Summer 2022. If successful, this study will inform a purchase decision for additional devices from SPD and will allow Fisher Wallace to market its solution to police departments and other first responder communities nationally.

Medicaid in Maine (MaineCare) became the first state Medicaid program to fully cover the purchase of the Fisher Wallace device. Broad insurance coverage is possible if the company obtains additional FDA Clearances and Approvals - however, at the current $499 retail price, the device is affordable to many patients out-of-pocket.

Version 2.0 will serve as an upgrade for the company's many Version 1.0 customers and is intended to provide brand leadership in the prescription wearable category for years to come.

*These products are currently under development and not yet available on the market.

why invest

Join us as we usher in a new era of mental health treatment

*These products are currently under development and not yet available on the market.

With years of product development, clinical research, regulatory and marketing experience, and over $30 million in lifetime revenue and $8 million in capital raised, our team is uniquely prepared to bring a refreshing vision of mental healthcare to life. We believe we possess the tech, talent, and timing required to successfully scale a new standard of care for those suffering from common mental health conditions. Become a shareholder in Fisher Wallace and help make mental health treatment better and more accessible for everyone. Invest $1500+ and receive the company’s Version 1.0 device (available now) or Version 2.0 device (available in 2023) for free!


630 Flushing Avenue, Suite #104
Brooklyn, NY 11206

Fisher Wallace manufactures and markets prescription-only brain stimulation wearables that have been cleared by the FDA to treat depression, anxiety, and insomnia. The technology comfortably stimulates the brain to produce serotonin, lower cortisol, and modulate brain activity. The company is VC-backed and led by CEO Kelly Roman, who has helped pioneer the category since 2009.


Charles "Chip" Fisher

Charles "Chip" Fisher

Co-Founder & Chairman & Director

Charles “Chip” Fisher grew up in the electronics business - his father, Avery Fisher, founded Fisher Radio (later renamed Fisher Electronics). After graduating from Harvard and serving as a sales executive at IBM, Chip acquired the original intellectual property to the Fisher Wallace Stimulator and is the company’s CFO and largest shareholder - and a recent TEDx contributor.

Jennifer "Fer" Wang

Jennifer "Fer" Wang

Chief Marketing Officer

Fer has nearly two decades of digital agency experience and is the complete social strategist, equally expert in paid social as in content development. As SVP Strategy at Likeable Media, Fer pushed her clients' social campaigns to ever higher levels of sophistication and measurable impact. At Fisher Wallace, Fer now has the opportunity to focus all of her energy and expertise on a single product and company that she truly believes in.

Kelly Roman

Kelly Roman

Co-Founder, CEO, and Director

For more than a decade, Kelly Roman has helped pioneer the prescription wearable category and has expertise in product development, regulatory affairs, healthcare marketing and clinical trial strategy. Prior to co-founding Fisher Wallace, Kelly graduated from Harvard and served as an award-winning executive in the digital advertising and SaaS industries. He recently served on the boards of two charter high schools in New York City.

Simon Webster

Simon Webster

Board Member

Simon is CEO of SHUFL Capital, the venture capital firm that recently invested in Fisher Wallace Laboratories. Simon's early career was spent in the UK financial services sector leading business change, delivering technology transformations and supporting M&A transactions. He led CPA Global on its 20 year journey from a £50m business to its recent public market entry at a value of £6.5bn. Simon has been investing in and working with founders of growth businesses in the SHUFL sectors since 2010.

Peter Rojas

Peter Rojas


Peter is currently Head of Product, NPE, at Meta, where he incubates the company's new and experimental products. Previously, Peter was a Partner at Betaworks Ventures, which invested in Giphy (sold to Facebook) among other startups, and co-founded the popular tech blogs Engadget and Gizmodo.


Fisher Wallace Laboratories
May 28, 2022
Class B Non-Voting Common Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares



Fisher Wallace Laboratories Inc.

Corporate Address


630 Flushing Avenue, Suite #104, Brooklyn, NY 11206

Offering Minimum



Offering Maximum



Minimum Investment Amount

(per investor)




Offering Type



Security Name


Class B Non-Voting Common Stock

Minimum Number of Shares Offered



Maximum Number of Shares Offered



Price per Share



Pre-Money Valuation



*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.

Investment Incentives and Bonuses*


Super Early Bird Bonus

Invest within the first 72 hours and receive 10% bonus shares.

Early Bird Bonus

Invest within the first week and receive 5% bonus shares.


$1,500+ | Tier 1

Invest $1,500 and receive 2% bonus shares + a free device. 

$5,000+ | Tier 2

Invest $5,000 and receive 5% bonus shares + a free device.

$10,000+ | Tier 3

Invest $10,000 and receive 10% bonus shares + a free device.

$25,000+ | Tier 4

Invest $25,000 and receive 15% bonus shares + a free device + a 30-minute zoom with our CEO.

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Fisher Wallace Laboratories Inc. will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Class B Non-Voting Common Stock at $8.76 / share, you will receive 110 shares Class B Non-Voting Common Stock, meaning you'll own 110 shares for $876. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will only receive a single bonus, which will be the highest bonus rate they are eligible for.

Irregular Use of Proceeds

We will not incur any irregular use of proceeds.


Article Image
Forbes Magazine

One of 4 Technologies Innovating Mental Health

Article Image

5 Health-Tech Startups to Watch in 2021

Article Image
Elle Magazine

Could A Shock-Delivering Headband Cure Depression?

Article Image
The Wall Street Journal

Using Electricity, Magnets for Mental Illness





A mental health comedy series on TikTok
Produced and directed by Kareem Rahma
Sponsored by Fisher Wallace Labs

Featuring: Kareem Rahma, Maddy Smith, Randall Otis, Neel Gosh, Chike Robinson, Nina Tarr, Joey Dardano, River Ramires, Sameer Naseem, Kelly Bachman, Johnny Gaffney, Jill Gonzales.

Watch the first clip featuring Kareem Rahma - Kareem is a force of nature on TikTok and the star of the short film OUT OF ORDER that premiered at the Tribeca Film Festival last weekend.

Follow the series to catch a fresh short every few days for the next eight weeks.

“We decided to fund a cultural event, not an ad campaign, that gives artists free rein to discuss mental health. Their views are their own, but the NYC based comedians in Unhappy Happy People share experiences that many of us will identify with - and by making us laugh, they take the power away from the taboo and give it back to us."

- Kelly Roman, CEO, Fisher Wallace Labs



Thank you investors and thank you StartEngine for making our campaign a tremendous success!

We look forward to everyone choosing their favorite color! 



Dear Investor, 

This is my last campaign update - our campaign will close at end of day. 

I'll leave you with a quote from the The Wall Street Journal interview with Dr. Richard Brown of Columbia University, published more than 10 years ago when we were just getting the business off the ground:

Does it work? Columbia University psychiatrist Richard P. Brown says he has used the device with 400 severely depressed patients and that more than 70% find relief—about twice the rate of anti-depressants. "I'm seeing some patients smile for the first time in 20 years," says Dr. Brown, who, like other doctors interviewed for this column, has no financial ties to the company.

- The Wall Street Journal, 1/11/11

Our depression trial currently underway will hopefully provide scientific data that mirrors Dr. Brown's clinical experience - if it does, we will be in a position to annex a significant portion of the depression treatment market. If it doesn't, we still have the positive results from our anxiety trial (conducted last year) to support a new FDA indication for Generalized Anxiety Disorder - it's important to note that nearly half of depression patients suffer from clinical anxiety, which means we can address patient symptoms one way or another. 


Kelly Roman

Co-Founder and CEO

Fisher Wallace Labs

Invest $1500+ to obtain a free device as a perk.



Dear Investors,

Thank you for once again pushing us over the $1 million raised milestone. Our campaign closes tomorrow, and the next few months promise to be an amazing ride:

- Our depression clinical trial is on track to complete recruitment by the end of June, allowing us to submit the data to the FDA in September, months before the December 11th deadline.  If we obtain a positive outcome, we will be in a position to become the first wearable device in history to receive FDA Approval to treat Major Depressive Disorder.  

- Between now and September, the FDA may render a decision on the anxiety study data we submitted last year - obtaining an indication for Generalized Anxiety Disorder would also be a first for a medical device company.

- Our pilot study with the Seattle Police Department is on track to conclude in July. We intend to leverage the data to build partnerships with other institutions and large employers and look forward to growing our new B2B channel as we scale our established B2C channel.

- Engineering of OAK (our Version 2.0 device) is on track to complete before the end of the summer, at which point we can begin the hand off to our tooling vendor.

- In June, we are launching a social media content series featuring 15 renowned New York City comedians who explore the challenges they've faced with their own mental health - a compelling, stigma-breaking, highly entertaining new approach to raising awareness. You will be the first to know when this is launched.

Achieving the above milestones will build enterprise value and cement our leadership position in a category - prescription wearables for mental health - that is in its infancy. 

We are still a start-up, but a mature one - we have over $30 million in lifetime revenue, over 80,000 customers, and multiple  clinical trials. Our Version 1.0 device, already on the market, faces no supply chain challenges - giving us all the time we need to  get OAK into production. I would not want to be a startup trying to get off the ground today - I am glad we are in a position of strength.

Thanks again,

Kelly Roman

Co-Founder & CEO

Fisher Wallace Labs

Invest $1500+ and receive OAK for free months before it's released to the general public.



Below is the letter our CEO Kelly Roman sent to 150,000 Fisher Wallace newsletter subscribers yesterday afternoon:

Dear Customer,

My daughter turns 8 next month. We live in New York and when she came home from from school last week after hearing about the mass shooting in Buffalo, she was afraid that she was going to be shot. Millions of parents are grappling with how to ease their children's fears, so I wanted to share a tactic that I found helpful - and am likely using again today.

When she brought up the shooting my mind raced to find a way to put the real risk of her being shot in perspective, in a way that's understandable to a child. I said, "Lets look on my phone and see what the odds are of getting hit by lightning. I'm pretty sure the odds of getting hit by lightning are better than you being shot." I do my best never to lie to my daughter and I've found using facts to reduce her anxiety is effective.

With her sitting by my side, watching me scan websites for data, here's what I found to support the argument: 1) According to the National Weather Service, the chance of being hit by lightning in your lifetime if you live to 80 years of age is 1 in 15,300. 2) According to the CDC, 8 children are intentionally shot every day on average. In a nation of 73 million children, that means the odds are 1 in 25,000 of a child being intentionally shot in a given year.

In order to soothe my daughter's anxiety, I went with this data as supporting evidence, even though I knew the comparison was flawed. I then turned our attention to the Guiness Book of World Records to find the person who had been hit by lightning the most and survived each time - a park ranger by the name of Roy Sullivan was hit 7 times. My daughter found this amazing, and I joked that after getting hit three times, Roy probably thought that would be the last time...and then the fourth time came, after which he probably thought the same, and then the fifth time happened. By this point my daughter was laughing.

The more relevant facts are very different. The National Weather Service reports the chance of getting hit by lightning in a given year (as opposed to a lifetime) is 1 in 1,220,000. The chance of a person being shot in the US for any reason - adult or child, intentionally or not - is only 1 in 3000. I'll wait for a different day to share those facts with my daughter.

I selected the data points needed to make the comparison work, and in doing so I turned the fear my daughter had of being shot into a moment of laughter. I was still using facts, but in a manipulative way - arguably the best choice given the circumstances. I would not use those same data points to help reduce an adult's anxiety.

Yesterday I worked such a long day I didn't see the news until 11pm. My daughter is certainly going to hear about the school shooting sometime today while at school. I'm leaving work early so I can join my wife in picking her up from the bus stop, about 10 blocks from where we live. I'm doing that to make myself feel better - to savor the privilege of picking her up. It's a privilege a lot of parents no longer have. If you are able to pick your child up today, I recommend it - I suspect you will remember picking them up on this particular day for a long time. I know I will.


Kelly Roman

CEO, Fisher Wallace Labs



View the pre-order site here.

To receive OAK for free, invest $1500+ in the remaining days of this campaign.



Allowing patients to choose the color of their depression treatment is a powerful way to uplift the treatment process and reduce stigma. A huge percentage of people with mental health symptoms never seek treatment - affordability and stigma are often to blame.

Our ultimate goal is to see the device become free for all customers through insurance - that will take time to materialize, and in the meantime we are keeping our device as affordable as possible out-of-pocket. Our partnership with the Seattle Police Department is an opportunity to demonstrate how employers will benefit by offering our technology to employees for free - improving employee performance, lowering sick days and lowering overall healthcare costs simply makes bottom-line sense.

We recently passed $1 million raised and there are 4 days left to invest. As always, invest $1500+ and receive a free Version 1 (available now) or Version 2 (available in 2023). We will start shipping Version 1 perk devices days after the campaign closes (SEC regulation demands that perk devices are only shipped after an investment has been disbursed, following the close of the campaign). Investors will receive a unique coupon code to obtain a free device through our website, which also provides a free prescription process (handled by our telemedicine partner, B2BMD).

Best regards,

Kelly Roman

Co-Founder & CEO

Fisher Wallace Labs



Two-time recipient of the Red Dot Award (the most prestigious award for an industrial designer), Eric Fields previously designed the first Nest thermostat and the Beats Pill (which made remarkable use of iridescent fabric). Above is a recent photo of his table in San Francisco with 3D-printed components of our Version 2.0 device. These components do not display the color and richness of our fabric choices, or the quality of world-class tooling and injecting molding - we look forward to sharing those details soon. Next week, we will introduce the brand name of Version 2.0, which we developed in collaboration with Pearlfisher. Stay tuned, and thank you for becoming an early investor in Fisher Wallace, one of the world's leading prescription wearable startups.




Dear Investors,

We're obsessed with science at Fisher Wallace. Our customer service team includes a biomechanical engineer and a doctoral student who studied in one of the nation's leading brain stimulation labs.

If you want to dive deep into the science behind our technology - called Transcranial Alternating Current Stimulation (tACS) - the best place to search is PubMed, the NIH's repository of published studies. Here's the link to 125 studies that have been published on tACS so far - the majority conducted using lab-built tACS devices. Our device is one of very few commercialized tACS devices, and our electrode placement and output are unique. CES (Cranial Electrotherapy Stimulation) is what tACS is called when it's regulated / marketed to treat depression, anxiety and/or insomnia. Here is one of our pilot studies on PubMed.

Best regards,

Kelly Roman

Co-founder and CEO

Fisher Wallace Labs

Our campaign closes in 9 days!



Dear Investors,

With 11 days left in our campaign, I want to highlight the bet we are making on FDA Approval. The FDA has given us until Dec 11, 2022 to file our approval application with new depression treatment data. This is why we recently launched a 250-subject Major Depressive Disorder study in collaboration with, a leading remote clinical trial platform, and NAMSA, one of the world's largest clinical research organizations (CRO). We anticipate completion of data collection by the end of August and completion of the research report in September, after which we'll be ready to submit to FDA well before the December deadline. It's important to submit the data before the deadline to allow for back-and-forth communications with the agency - this communication time is deducted from the submission clock (if a company were to submit on Dec 10, there would be almost no time allowed for communication).

We do not know if our depression trial is going to succeed - there are many variables that can impact results. What we do have are strong signals from previous research, such as our smaller bipolar depression study which was published in 2015, and the avalanche of positive reviews we've received from patients and prescribers. But clinical trials are tricky because of the enormous number of exclusion and inclusion criteria applied to recruitment, in order to get a "pure" patient population for an FDA indication - for every patient admitted into the trial, far more will be excluded. This is very different than the real-world commercial sales process which is open to a wide array of patients - essentially, to any patient suffering from depression. A mental health clinical trial almost always examines only a small slice of the overall patient population - therefore, the signals we have are just signals, not a guarantee of success.

If we succeed, we will likely become the first wearable technology to  receive FDA Approval to treat depression - a status that would transfer to our Version 2 device as we are taking great care to ensure it delivers identical treatment (albeit in a much more attractive form factor).

The stakes are very high - and we may fail.  But such risks must be taken to truly transform depression treatment on a global scale.

Best regards

Kelly Roman

CEO, Fisher Wallace Labs


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Fisher Wallace Laboratories.


StartEngine Owner’s Bonus

This offering is eligible for the StartEngine Owner’s 10% Bonus program. For details on this program, please see the Offering Summary section below.


Tier 1

Invest $1,500 and receive 2% bonus shares + a free device.


Tier 2

Invest $5,000 and receive 5% bonus shares + a free device.


Tier 3

Invest $10,000 and receive 10% bonus shares + a free device.


Tier 4

Invest $25,000 and receive 15% bonus shares + a free device + a 30-minute zoom with our CEO.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.